Symbiotec Pharmalab's Initial Public Offering closed with an overwhelming response, getting subscribed 71.26 times. The steroid and hormone API manufacturer saw massive institutional and high-net-worth investor demand.
93.52 crore
Total Shares Bid For
Shares Offered: 1.31 crore→93.52 crore
Symbiotec Pharmalab’s IPO closed its bidding window on Thursday with an impressive 71.26x oversubscription, highlighting the intense retail and institutional demand in India’s primary markets. The company received bids for 93.52 crore shares against the 1.31 crore shares on offer. Specializing in steroid-based hormones and cortico-steroids, the active pharmaceutical ingredient manufacturer is poised for a strong stock exchange debut on September 1. This massive subscription highlights the growing investor appetite for specialized healthcare suppliers benefiting from global supply chain shifts.
💭 If you're wondering…
Corticosteroids are specialized steroid hormones used to treat inflammatory conditions, allergies, and immune disorders, representing a high-margin, technically demanding segment of the drug market.
Did this story help?
Official sources
Knowledge Chain — tap a concept